

T-cell lymphoma models: Defining molecular mechanisms of resistance. *International Journal of Cancer*, 127(9), 2199-2208.

Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., ... & Ferrara, N. (2007). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+ Gr1+ myeloid cells. *Nature biotechnology*, 25(8), 911-920.

Shou, Y., Hirano, T., Gong, Y., Kato, Y., Yoshida, K., Ohira, T., ... & Kato, H. (2001). Influence of angiogenic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. *British journal of cancer*, 85(11), 1706.

Sidhu, R. S., Lee, J. Y., Yuan, C., & Smith, W. L. (2010). Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers. *Biochemistry*, 49(33), 7069-7079.

Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. *CA: a cancer journal for clinicians*, 62(1), 10-29.

Siegel, R., Ward, E., Brawley, O., & Jemal, A. (2011). Cancer statistics, 2011. *CA: a cancer journal for clinicians*, 61(4), 212-236.

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. *Science*, 305(5687), 1163-1167.

Sund, M., Hamano, Y., Sugimoto, H., Sudhakar, A., Soubasakos, M., Yerramalla, U., ... & Kalluri, R. (2005). Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. *Proceedings of the National Academy of Sciences of the United States of America*, 102(8), 2934-2939.